NeuroPace, Inc. (NASDAQ:NPCE ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Jeremy Feffer - Investor Relations Joel Becker - Chief Executive Officer and Board Member Rebecca Kuhn - Chief Financial Officer, Vice President, Finance and Administration Conference Call Participants Priya Sachdeva - UBS Rohin Patel - JP Morgan Frank Takkinen - Lake Street Capital Markets Mike Kratky - Leerink Partners Vik Chopra - Wells Fargo Matthew Park - Cantor Fitzgerald Michael Pollard - Wolfe Research Operator Greetings and welcome to NeuroPace Fourth Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.
-- Record quarterly revenue of $21.5 million in Q4 2024 -- -- Full-year 2025 revenue guidance of $92 to $96 million --
NeuroPace (NPCE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
MOUNTAIN VIEW, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter and full year of 2024 after market close on Tuesday, March 4, 2025.
MOUNTAIN VIEW, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE) today announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $10.00 per share.
MOUNTAIN VIEW, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE) today announced that it intends to offer and sell, in an underwritten public offering, $65 million of shares of its common stock. All of the shares are being offered by NeuroPace. In addition, NeuroPace intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
MOUNTAIN VIEW, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that an abstract featuring data from the Post-approval Study of the RNS System has been selected for an oral presentation at the upcoming American Academy of Neurology (AAN) 2025 Annual Meeting, which is being held April 5th – 9th in San Diego.
– 2025 revenue guidance of $92 million to $96 million – – 2025 gross margin guidance of 73% to 75% – – Three-year targets of 20% revenue CAGR and achievement of cash flow breakeven – MOUNTAIN VIEW, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today issued 2025 financial guidance targets at an in-person and virtual Investor Day today in New York, New York (a replay can be viewed virtually here, and the accompanying slide presentation can be accessed here).
NeuroPace (NPCE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Preliminary unaudited revenue expected to be between $21.0 million and $21.5 million for Q4 2024, and between $79.4 million and $79.9 million for full year 2024